Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;63(5):640-650.
doi: 10.1002/mus.27099. Epub 2020 Nov 6.

Skeletal muscle magnetic resonance imaging in Pompe disease

Affiliations
Review

Skeletal muscle magnetic resonance imaging in Pompe disease

Jordi Díaz-Manera et al. Muscle Nerve. 2021 May.

Abstract

Pompe disease is characterized by a deficiency of acid alpha-glucosidase that results in muscle weakness and a variable degree of disability. There is an approved therapy based on enzymatic replacement that has modified disease progression. Several reports describing muscle magnetic resonance imaging (MRI) features of Pompe patients have been published. Most of the studies have focused on late-onset Pompe disease (LOPD) and identified a characteristic pattern of muscle involvement useful for the diagnosis. In addition, quantitative MRI studies have shown a progressive increase in fat in skeletal muscles of LOPD over time and they are increasingly considered a good tool to monitor progression of the disease. The studies performed in infantile-onset Pompe disease patients have shown less consistent changes. Other more sophisticated muscle MRI sequences, such as diffusion tensor imaging or glycogen spectroscopy, have also been used in Pompe patients and have shown promising results.

Keywords: Pompe disease; acid maltase; glycogenosis; muscle MRI; skeletal muscle.

PubMed Disclaimer

References

REFERENCES

    1. Martiniuk F, Bodkin M, Tzall S, Hirschhorn R. Isolation and partial characterization of the structural gene for human acid alpha glucosidase. DNA Cell Biol. 1991;10:283-292.
    1. Lim J, Li L, Raben N. Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci. 2014;6:1-14.
    1. van der Beek NA, Hagemans ML, van der Ploeg AT, Reuser AJ, van Doorn PA. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy. Acta Neurol Belg. 2006;106:82-86.
    1. Bembi B, Cerini E, Danesino C, et al. Diagnosis of glycogenosis type II. Neurology. 2008;71(Suppl):S4-S11.
    1. Echaniz-Laguna A, Carlier RY, Laloui K, et al. Should patients with asymptomatic pompe disease be treated? A nationwide study in France. Muscle Nerve. 2015;51:884-889.

Publication types

MeSH terms